Cargando…

Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report

KEY CLINICAL MESSAGE: In conclusion author highlights the tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC. ABSTRACT: An uncommon form of non‐small‐cell lung cancer (NSCLC) with a po...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Wei, Wang, Xinlian, Shi, Qifeng, Li, Xiao, Chen, Chaobo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196425/
https://www.ncbi.nlm.nih.gov/pubmed/37215977
http://dx.doi.org/10.1002/ccr3.7365
_version_ 1785044351116640256
author Sun, Wei
Wang, Xinlian
Shi, Qifeng
Li, Xiao
Chen, Chaobo
author_facet Sun, Wei
Wang, Xinlian
Shi, Qifeng
Li, Xiao
Chen, Chaobo
author_sort Sun, Wei
collection PubMed
description KEY CLINICAL MESSAGE: In conclusion author highlights the tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC. ABSTRACT: An uncommon form of non‐small‐cell lung cancer (NSCLC) with a poor prognosis is pulmonary sarcomatoid carcinoma (PSC). Surgical resection is currently the preferred treatment, but guidelines for adjuvant chemotherapy have not yet been established, especially for the advanced stage. The development of molecular subgroups in the field of tumors may be advantageous to advanced PSC patients with the ongoing progress of genomics and immunology. A 54‐year‐old man presented to Xishan People's Hospital of Wuxi City with recurrent intermittent dry cough with fever for 1 month. Further examinations suggested the diagnosis of PSC occupying almost the entire right interlobar fissure area combined with malignant pleural effusion (Stage IVa). Pathological examination confirmed the diagnosis of PSC with ROS1 overexpressing via genetic testing. However, after three cycles of chemo‐, antiangiogenetic‐ and immunochemical therapy, the lesion was localized, and pleural effusion disappeared, the patient subsequently received an operation which was performed as R0 resection. Unfortunately, the patient became deteriorated quickly followed by extensive metastatic nodules in the thoracic cavity. Although the patient continued to receive chemo‐ and immunochemical‐therapy, it did not limit the progress of the tumor, leading to widespread metastasis, and eventually died of multiple organ failure. For PSC patients with Stage IVa, chemo‐, antiangiogenetic‐ and immunochemical‐therapy performs well in clinical efficacy, and comprehensive panel‐based genetic testing may offer PSC patients a somewhat better prognosis. However, blindly implementing surgical treatment may bring harm to the patient and affect long‐term survival. It's essential to know the surgical indications precisely by NSCLC guidelines.
format Online
Article
Text
id pubmed-10196425
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101964252023-05-20 Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report Sun, Wei Wang, Xinlian Shi, Qifeng Li, Xiao Chen, Chaobo Clin Case Rep Case Report KEY CLINICAL MESSAGE: In conclusion author highlights the tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC. ABSTRACT: An uncommon form of non‐small‐cell lung cancer (NSCLC) with a poor prognosis is pulmonary sarcomatoid carcinoma (PSC). Surgical resection is currently the preferred treatment, but guidelines for adjuvant chemotherapy have not yet been established, especially for the advanced stage. The development of molecular subgroups in the field of tumors may be advantageous to advanced PSC patients with the ongoing progress of genomics and immunology. A 54‐year‐old man presented to Xishan People's Hospital of Wuxi City with recurrent intermittent dry cough with fever for 1 month. Further examinations suggested the diagnosis of PSC occupying almost the entire right interlobar fissure area combined with malignant pleural effusion (Stage IVa). Pathological examination confirmed the diagnosis of PSC with ROS1 overexpressing via genetic testing. However, after three cycles of chemo‐, antiangiogenetic‐ and immunochemical therapy, the lesion was localized, and pleural effusion disappeared, the patient subsequently received an operation which was performed as R0 resection. Unfortunately, the patient became deteriorated quickly followed by extensive metastatic nodules in the thoracic cavity. Although the patient continued to receive chemo‐ and immunochemical‐therapy, it did not limit the progress of the tumor, leading to widespread metastasis, and eventually died of multiple organ failure. For PSC patients with Stage IVa, chemo‐, antiangiogenetic‐ and immunochemical‐therapy performs well in clinical efficacy, and comprehensive panel‐based genetic testing may offer PSC patients a somewhat better prognosis. However, blindly implementing surgical treatment may bring harm to the patient and affect long‐term survival. It's essential to know the surgical indications precisely by NSCLC guidelines. John Wiley and Sons Inc. 2023-05-18 /pmc/articles/PMC10196425/ /pubmed/37215977 http://dx.doi.org/10.1002/ccr3.7365 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sun, Wei
Wang, Xinlian
Shi, Qifeng
Li, Xiao
Chen, Chaobo
Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report
title Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report
title_full Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report
title_fullStr Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report
title_full_unstemmed Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report
title_short Comprehensive treatment for ROS1 ‐overexpressed pulmonary sarcomatoid carcinoma: A case report
title_sort comprehensive treatment for ros1 ‐overexpressed pulmonary sarcomatoid carcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196425/
https://www.ncbi.nlm.nih.gov/pubmed/37215977
http://dx.doi.org/10.1002/ccr3.7365
work_keys_str_mv AT sunwei comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport
AT wangxinlian comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport
AT shiqifeng comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport
AT lixiao comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport
AT chenchaobo comprehensivetreatmentforros1overexpressedpulmonarysarcomatoidcarcinomaacasereport